{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Valneva SE"},"Symbol":{"label":"Symbol","value":"VALN"},"Address":{"label":"Address","value":"6 RUE ALAIN BOMBARD,GERLAND PLAZA TECHSUD, SAINT-HERBLAIN, 44800, France"},"Phone":{"label":"Phone","value":"+33 228073710"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travellers; one for the prevention of Japanese encephalitis (IXIARO) and the second (DUKORAL) for the prevention of cholera and diarrhoea. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, and third-party products; Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; and Technologies and services which relates to services and inventions at a commercialization stage. The group is based in France and operates internationally."},"CompanyUrl":{"label":"Company Url","value":"https://www.valneva.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Hanneke Schuitemaker","title":"Chief Scientific Officer"},{"name":"Juan Carlos Jaramillo","title":"Chief Medical Officer"},{"name":"Thomas Lingelbach","title":"President, Chief Executive Officer & Director"},{"name":"Vincent Dequenne","title":"Chief Operating Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}